Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Nov 19

PMID 31737567

Citations 19

Authors

Aurelie Moreau

Olivia Febvey

Thomas Mognetti

Didier Frappaz

David Kryza

Affiliations

Soon will be listed here.

Abstract

Although rare, glioblastomas account for the majority of primary brain lesions, with a dreadful prognosis. Magnetic resonance imaging (MRI) is currently the imaging method providing the higher resolution. However, it does not always succeed in distinguishing recurrences from non-specific temozolomide, have been shown to improve -related changes caused by the combination of radiotherapy, chemotherapy, and targeted therapy, also called pseudoprogression. Strenuous attempts to overcome this issue is highly required for these patients with a short life expectancy for both ethical and economic reasons. Additional reliable information may be obtained from positron emission tomography (PET) imaging. The development of this technique, along with the emerging of new classes of tracers, can help in the diagnosis, prognosis, and assessment of therapies. We reviewed the current data about the commonly used tracers, such as 18F-fluorodeoxyglucose (18F-FDG) and radiolabeled amino acids, as well as different PET tracers recently investigated, to report their strengths, limitations, and relevance in glioblastoma management.

Citing Articles

An effective MRI perfusion threshold based workflow to triage additional F-FET PET in posttreatment high grade glioma.

Kadali K, Nierobisch N, Maibach F, Heesen P, Alcaide-Leon P, Hullner M Sci Rep. 2025; 15(1):7749.

PMID: 40044711 PMC: 11882894. DOI: 10.1038/s41598-025-90472-8.

ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes.

Moltoni G, Romano A, Capriotti G, Campagna G, Ascolese A, Romano A Radiol Med. 2024; 129(9):1382-1393.

PMID: 39117936 PMC: 11379733. DOI: 10.1007/s11547-024-01862-3.

Cudraflavone B induces human glioblastoma cells apoptosis via ER stress-induced autophagy.

Pan J, Zhao R, Dong C, Yang J, Zhang R, Sun M BMC Neurosci. 2023; 24(1):10.

PMID: 36721107 PMC: 9890863. DOI: 10.1186/s12868-023-00778-4.

The Role of PET Imaging in the Differential Diagnosis between Radiation Necrosis and Recurrent Disease in Irradiated Adult-Type Diffuse Gliomas: A Systematic Review.

Ninatti G, Pini C, Gelardi F, Sollini M, Chiti A Cancers (Basel). 2023; 15(2).

PMID: 36672314 PMC: 9856914. DOI: 10.3390/cancers15020364.

Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know.

Soni N, Ora M, Jena A, Rana P, Mangla R, Ellika S AJNR Am J Neuroradiol. 2023; 44(3):236-246.

PMID: 36657945 PMC: 10187808. DOI: 10.3174/ajnr.A7762.

References

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H . O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011; 52(6):856-64. DOI: 10.2967/jnumed.110.086645. View

Ellingson B, Chung C, Pope W, Boxerman J, Kaufmann T . Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017; 134(3):495-504. PMC: 7893814. DOI: 10.1007/s11060-017-2375-2. View

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9(5):453-61. DOI: 10.1016/S1470-2045(08)70125-6. View

Sasikumar A, Joy A, Pillai M, Nanabala R, Anees K M, Jayaprakash P . Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis. Clin Nucl Med. 2016; 42(1):e41-e48. DOI: 10.1097/RLU.0000000000001451. View

Kamson D, Mittal S, Robinette N, Muzik O, Kupsky W, Barger G . Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma. Neuro Oncol. 2014; 16(10):1373-83. PMC: 4165412. DOI: 10.1093/neuonc/nou042. View

Suchorska B, Jansen N, Linn J, Kretzschmar H, Janssen H, Eigenbrod S . Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7):710-9. DOI: 10.1212/WNL.0000000000001262. View

Youland R, Kitange G, Peterson T, Pafundi D, Ramiscal J, Pokorny J . The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2012; 111(1):11-8. PMC: 3907171. DOI: 10.1007/s11060-012-0986-1. View

Kwee S, Ko J, Jiang C, Watters M, Coel M . Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007; 244(2):557-65. DOI: 10.1148/radiol.2442060898. View

Chen W . Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48(9):1468-81. DOI: 10.2967/jnumed.106.037689. View

10.

Nomura N, Pastorino S, Jiang P, Lambert G, Crawford J, Gymnopoulos M . Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014; 14(1):26. PMC: 3994554. DOI: 10.1186/1475-2867-14-26. View

11.

Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View

12.

De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S . FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol. 2001; 49(2):157-63. DOI: 10.1023/a:1026518002800. View

13.

Mahzouni P, Shavakhi M . Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme. Adv Biomed Res. 2019; 8:18. PMC: 6425742. DOI: 10.4103/abr.abr_209_18. View

14.

Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D . Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23(10):2372-7. DOI: 10.1200/JCO.2005.00.331. View

15.

Rachinger W, Goetz C, Popperl G, Gildehaus F, Kreth F, Holtmannspotter M . Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005; 57(3):505-11. DOI: 10.1227/01.neu.0000171642.49553.b0. View

16.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

17.

Floeth F, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W . 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med. 2006; 47(5):776-82. View

18.

Bund C, Heimburger C, Imperiale A, Lhermitte B, Chenard M, Lefebvre F . FDOPA PET-CT of Nonenhancing Brain Tumors. Clin Nucl Med. 2017; 42(4):250-257. DOI: 10.1097/RLU.0000000000001540. View

19.

Filss C, Galldiks N, Stoffels G, Sabel M, Wittsack H, Turowski B . Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014; 55(4):540-5. DOI: 10.2967/jnumed.113.129007. View

20.

Popperl G, Kreth F, Herms J, Koch W, Mehrkens J, Gildehaus F . Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med. 2006; 47(3):393-403. View